Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:05:41 16/01/2026 GMT			5-day change	1st Jan Change
18.10 ^USD	+0.19%		+0.56%	-12.52%

01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI
11-13	Gene therapy developer Neurogene's Q3 net loss widens	RE

Neurogene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025

Published on 08/11/2025 at 09:06 pm BST

S&P Capital IQ

Neurogene Inc.

+0.19%

Neurogene Inc. reported earnings results for the second quarter and six months ended June 30, 2025. For the second quarter, the company reported net loss was USD 22.02 million compared to USD 18.49 million a year ago. Basic loss per share from continuing operations was USD 1.05 compared to USD 1.09 a year ago.
For the six months, net loss was USD 44.66 million compared to USD 35.41 million a year ago. Basic loss per share from continuing operations was USD 2.12 compared to USD 2.09 a year ago.

Latest news about Neurogene Inc.

01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI
11-13	Gene therapy developer Neurogene's Q3 net loss widens	RE
11-13	Neurogene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Neurogene Inc. Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome Multidomain	CI
11-12	Neurogene Inc. Presents at Stifel 2025 Healthcare Conference, Nov-12-2025 04:40 PM
11-06	Neurogene Doses First Patient in Registrational Trial of NGN-401 for Rett Syndrome	MT
11-06	Neurogene Inc. Announces First Participant Dosed in Embolden?? Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome	CI
09/10/25	Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Fourth Quarter of 2025	CI
09/10/25	Neurogene Shares Rise After NGN-401 Discussions With FDA	DJ
09/10/25	Neurogene Plans to Initiate Dosing in Registrational Trial in Q4 2025	MT
03/10/25	Neurogene announces inducement grants under Nasdaq Listing Rule	RE
05/09/25	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
11/08/25	Neurogene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
08/08/25	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
30/06/25	Neurogene Inc. Announces Registrational Trial Design for Embolden? Study of NGN-401 Gene Therapy for Rett Syndrome	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell Microcap Growth Index	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 3000E Growth Index	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 2500 Growth Index	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 2000 Growth Index	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 3000 Growth Index	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell Small Cap Comp Growth Index	CI
29/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell Small Cap Comp Growth Benchmark	CI
29/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 3000E Growth Benchmark	CI
29/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 3000 Growth Benchmark	CI
29/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 2500 Growth Benchmark	CI

Chart Neurogene Inc.

Duration

Period

NGNE: Dynamic Chart

Company Profile

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Employees

107

Sector

Biotechnology & Medical Research

Calendar

03-22 - Q4 2025 Earnings Release (Projected)

More about the company